DrEhsanGhorani

Faculty of Medicine, Department of Surgery & Cancer

Clinical Senior Lecturer in Medical Oncology

Contact

Location

Commonwealth BuildingHammersmith Campus

Summary

Dr. Ehsan Ghorani is a CRUK Clinician Scientist Fellow in cancer immunology and consultant medical oncologist with a focus on gestational and lung cancer.

The Cancer Immunology and Immunotherapy Unit

How do cancers evade the immune response and what mediates immunotherapy sensitivity?

What should we target to maximise patient responses?

Can we predict patient outcomes and personalise therapies around this?

Our lab is particularly interested in gestatational cancers as a human model of cancer immune regulation, since these tumours are unique in arising from non-self placental trophoblast cells. How does this allograft tissue evade immune escape?

In parallel, we showed in 2017 that gestational cancers are exquisitely sensitive to immunotherapy with the majority of patients cured of metastatic disease using drugs that target the T cell inhibitory receptor PD1. What mediates such profound immunotherapy sensitivity?

We hope that by studying these extremes of immune regulation we can learn mechanisms of immune evasion and immunotherapy sensitivity that are relevant to more common cancers.

As co-PI and Translational Lead for two large investigator led immunotherapy trials; the phase III REFINE-Lung and phase II REFINE-Basket studies, our lab has unique access to patient samples to address these questions.

Prospective students and postdocs are always welcome to get in touch.

Google scholar

Twitter

Selected Publications

Journal Articles

Qing C, Ghorani E, 2023, Two faces: IL-22 effects prevail over defense against metastasis., Immunity, Vol:56, Pages:6-8

Solomon I, Amann M, Goubier A, et al.Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, Henry JY, Ghorani E, Akarca AU, Marafioti T, sledzinska A, Werner Sunderland M, Franz Demane D, Clancy JR, Georgiou A, Salimu J, Merchiers P, Brown MA, Flury R, Eckmann J, Murgia C, Sam J, Jacobsen B, Marrer-Berger E, Boetsch C, Belli S, Leibrock L, Benz J, Koll H, Sutmuller R, Peggs KS, Quezada SA close, 2020, CD25-T<sub>reg</sub>-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity, Nature Cancer, Vol:1, Pages:1153-+

Alrasheed N, Lee L, Ghorani E, et al.Alrasheed N, Lee L, Ghorani E, Henry JY, Conde L, Chin M, Galas-Filipowicz D, Furness AJS, Chavda SJ, Richards H, De-Silva D, Cohen OC, Patel D, Brooks A, Rodriguez-Justo M, Pule M, Herrero J, Quezada SA, Yong KL close, 2020, Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma., Clin Cancer Res, Vol:26, Pages:3443-3454

Ghorani E, Reading JL, Henry JY, et al.Ghorani E, Reading JL, Henry JY, Massy MRD, Rosenthal R, Turati V, Joshi K, Furness AJS, Ben Aissa A, Saini SK, Ramskov S, Georgiou A, Sunderland MW, Wong YNS, Mucha MVD, Day W, Galvez-Cancino F, Becker PD, Uddin I, Oakes T, Ismail M, Ronel T, Woolston A, Jamal-Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Litchfield K, Conde L, Guerra-Assunção JA, Blighe K, Biswas D, Salgado R, Lund T, Bakir MA, Moore DA, Hiley CT, Loi S, Sun Y, Yuan Y, AbdulJabbar K, Turajilic S, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS, McGranahan N, Chain B, TRACERx Consortium, Swanton C, Quezada SA close, 2020, The T cell differentiation landscape is shaped by tumour mutations in lung cancer., Nat Cancer, Vol:1, Pages:546-561

More Publications